Workflow
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SCYXSCYNEXIS(SCYX) GlobeNewswire News Room·2024-11-06 21:30

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a 10milliondevelopmentmilestonepaymenttoSCYNEXIS,receivedinQ32024.SCY−247preclinicalstudieswerepresentedatmedicalconferencesandcontinuetoshowpotentandbroadantifungalactivity.Phase1studyinitiationisanticipatedinQ42024.SCYNEXISendedQ32024withcash,cashequivalentsandinvestmentsof10 million development milestone payment to SCYNEXIS, received in Q3 2024. SCY-247 preclinical studies were presented at medical conferences and continue to show potent and broad antifungal activity. Phase 1 study initiation is anticipated in Q4 2024. SCYNEXIS ended Q3 2024 with cash, cash equivalents and investments of 84.9 million, including the recently ...